CAR T-Cell Therapy for Lupus Nephritis
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing a new treatment that uses modified immune cells to target and destroy harmful cells in adults with severe kidney inflammation from lupus that doesn't respond to usual treatments.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is CAR T-Cell Therapy safe for humans?
How is the treatment KYV-101 for lupus nephritis different from other treatments?
KYV-101, a CAR T-cell therapy, is unique because it uses modified immune cells to target and destroy specific B cells involved in lupus nephritis, potentially leading to long-term remission without ongoing medication. This approach differs from traditional treatments like corticosteroids and immunosuppressive drugs, which broadly suppress the immune system and often have significant side effects.12356
What data supports the effectiveness of the treatment KYV-101, Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, for lupus nephritis?
Research shows that anti-CD19 CAR T-cell therapy has been effective in treating systemic lupus erythematosus (SLE), a related condition, by reducing disease activity and achieving remission in patients who did not respond to other treatments. This suggests potential effectiveness for lupus nephritis, which is a kidney-related complication of SLE.12367
Who Is on the Research Team?
MD
Principal Investigator
Kyverna Therapeutics
Are You a Good Fit for This Trial?
This trial is for adults over 18 with a clinical diagnosis of Systemic Lupus Erythematosus (SLE) who meet specific criteria, including positive tests for certain autoantibodies and biopsy-proven proliferative lupus nephritis. Participants must be up to date on vaccinations, including COVID-19. Those with severe neurological disorders, active hepatitis B or C, HIV, primary immunodeficiency, significant heart disease or previous malignancies (with some exceptions), or prior cellular/gene therapy are excluded.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Lymphodepletion Conditioning
Participants undergo lymphodepletion conditioning prior to receiving KYV-101 CAR T cells
Treatment
Participants receive KYV-101 CAR T-cell therapy
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- KYV-101
KYV-101 is already approved in United States for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Kyverna Therapeutics
Lead Sponsor